S9031-S9126-S9333-S9500-A, Examination of the Prognostic Significance of AML-Specific and Age-Associated Genes in AML Patients
18 Years
N/A
Both
Leukemia
Trial Information
S9031-S9126-S9333-S9500-A, Examination of the Prognostic Significance of AML-Specific and Age-Associated Genes in AML Patients
OBJECTIVES:
- To determine whether the expression of previously identified acute myeloid leukemia
(AML)-specific and age-associated genes have prognostic significance in adult patients
with AML.
- To examine, preliminarily, if AML-specific and age-associated expression changes occur
in the most primitive hematopoietic leukemia blasts (i.e., CD34+/38-).
- To examine, preliminarily, whether methylation or histone modification of the IRF8 CPG
island/promoter region is correlated with IRF8 gene expression in AML.
OUTLINE: This is a multicenter study.
Previously collected specimens of RNA from pre-treatment marrow or peripheral blood are
obtained from a repository of SWOG clinical trials (SWOG-S9031, SWOG-9126, SWOG-9333, and
SWOG-9500). Samples are analyzed for absolute expression levels of 23 selected genes and
relative expression levels of splice variants via quantitative RT/PCR and GeneScan assays
and linked to clinical and outcome data from the main SWOG database. Samples from a subset
of patients are analyzed to confirm aberrant expression of acute myeloid leukemia-specific
and age-associated genes in highly enriched population of leukemic blasts (CD34+/CD38- and
CD34+/CD38+). DNA samples are also analyzed for correlation of IRF8 gene expression with
methylation or histone modification of the IRF8 CPG island/promoter region.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Pretreatment RNA specimens* available from patients with acute myeloid leukemia (AML)
registered for front-line therapy on the following clinical trials:
- SWOG-9031
- SWOG-9126
- SWOG-9333
- SWOG-9500
- Cryopreserved pretreatment cell specimens* available from a subset of patients (those
who obtained a complete response [CR] and remained in CR without relapse for ≥ 2
years vs those with resistant disease [i.e., failed to achieve CR with evidence of
persistent AML following induction therapy]) NOTE: All specimens currently available
in the Southwest Oncology Group Myeloid Leukemia and MDS Repository at the University
of New Mexico
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Outcome Measure:
Prognostic significance for complete response, overall survival, and relapse-free survival of total and relative expression levels (variant/wild type ratios) for each gene
Outcome Time Frame:
immediate
Safety Issue:
No
Principal Investigator
Derek L. Stirewalt, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Fred Hutchinson Cancer Research Center
Authority:
United States: Federal Government
Study ID:
CDR0000614113
NCT ID:
NCT00899171
Start Date:
November 2008
Completion Date:
September 2012
Related Keywords:
- Leukemia
- adult acute myeloid leukemia in remission
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- recurrent adult acute myeloid leukemia
- untreated adult acute myeloid leukemia
- adult acute erythroid leukemia (M6)
- adult acute megakaryoblastic leukemia (M7)
- adult acute minimally differentiated myeloid leukemia (M0)
- adult acute monoblastic leukemia (M5a)
- adult acute monocytic leukemia (M5b)
- adult acute myeloblastic leukemia with maturation (M2)
- adult acute myeloblastic leukemia without maturation (M1)
- adult acute myelomonocytic leukemia (M4)
- secondary acute myeloid leukemia
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
